Northwire Canada EditionWednesday, July 15, 2026
Northwire
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%
M&A / Property

iFabric & Doctor's Choice(R) Sign Next-Generation Scrubs & Medical Apparel Agreement

IFA · Price

Executive Summary

  • iFabric’s subsidiary Intelligent Fabric Technologies (North America) Inc. (IFTNA) signed a license agreement with Mercury Athletics LLC to design, manufacture and market Doctor’s Choice® branded scrubs and medical apparel.
  • The program will incorporate IFTNA’s PROTX2® textile technology, offering antibacterial, antimicrobial and odor‑control properties for healthcare apparel.
  • The partnership leverages iFabric’s recently published peer‑reviewed clinical trial on PROTX2®, positioning the new product line as an infection‑prevention solution for hospitals, clinics and dental offices.

Key Details

  • Parties: iFabric Corp. (TSX: IFA) – wholly owned subsidiary IFTNA; Mercury Athletics LLC (owner of Doctor’s Choice® brand).
  • Scope: Design, manufacture, and market Doctor’s Choice “scrubs” (tops and pants) across professional healthcare sales channels. Additional product details, timelines, and retail partners to be announced as programs finalize.
  • Technology: PROTX2® – eco‑friendly treatment providing antibacterial, antimicrobial, anti‑mold, anti‑mildew, and anti‑odor protection; cited as a next‑generation infection‑prevention tool for medical textiles.
  • Clinical Validation: iFabric’s peer‑reviewed clinical trial published in 2025 in the Journal of Hospital Infection (link provided) supports the efficacy of PROTX2® technology.
  • Strategic Rationale: Extends the well‑known Doctor’s Choice brand from diabetic/compression socks into broader healthcare apparel, deepening iFabric’s product‑technology relationship and opening new revenue streams in the medical apparel market.
  • Leadership Quotes:
  • Ty Schultz, President of Mercury Athletics LLC – highlighted the alignment of wellness solutions with comfort and performance.
  • Giancarlo Beevis, President & CEO of IFTNA – emphasized the combination of a trusted brand with field‑proven textile science for infection‑prevention tools.

Notable Quotes

  • “Doctor’s Choice is all about practical wellness‑solutions that feel great and perform when it matters most… we’re thrilled to bring that promise into scrubs, with IFTNA's technologies at the core.” – Ty Schultz, President, Mercury Athletics LLC
  • “This partnership unites a trusted healthcare brand with field‑proven textile science… these scrubs represent the next generation of infection‑prevention tools—truly the doctors' choice… and nurses' and dentists', too.” – Giancarlo Beevis, President & CEO, IFTNA
Read the original news release →

More from IFABRIC CORP. J